Neuraptive Therapeutics kondigt belangrijke organisatorische updates aan om de vooruitgang van het bedrijf op het gebied van zenuwherstel te ondersteunen
- Evan Tzanis werd benoemd tot Chief Operating Officer
- Seth Schulman, M.D. treedt toe als Chief Medical Officer
- Conversie van alle voorgaande notes in preferente aandelen
PHILADELPHIA–(BUSINESS WIRE)– Neuraptive Therapeutics, Inc., een biotechnologiebedrijf dat zich toelegt op de ontwikkeling van nieuwe therapieën en medische producten om te voorzien in de onvervulde behoeften van artsen en patiënten die worden getroffen door perifere zenuwletsels, heeft belangrijke organisatorische en financiële updates aangekondigd.
Evan Tzanis is benoemd tot Chief Operating Officer en Executive Vice President van Onderzoek en Ontwikkeling. De heer Tzanis had de rol van Executive Vice President of Research en Development bekleed sinds hij in 2019 bij Neuraptive kwam, en zal blijven rapporteren aan Robert Radie, voorzitter en CEO. De heer Tzanis heeft het bedrijf geleid van een preklinisch gericht bedrijf naar een klinisch gefaseerd bedrijf met twee actieve goedgekeurde IND’s en twee fase 2-klinische onderzoeken met Fast Track-aanduiding. Daarnaast heeft dhr. Tzanis een integrale rol gespeeld bij het begeleiden van het bedrijf bij een belangrijke organisatorische transitie en fondsenwerving.
Neuraptive Therapeutics Announces Key Organizational Updates to Support the Company’s Advancements in Nerve Repair
- Evan Tzanis was appointed to the role of Chief Operating Officer
- Seth Schulman, M.D. joins as Chief Medical Officer
- Conversion of all previous notes into preferred shares
PHILADELPHIA–(BUSINESS WIRE)– Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announced key organizational and financial updates.
Evan Tzanis has been appointed to the role of Chief Operating Officer and Executive Vice President of Research and Development. Mr. Tzanis had served in the role of Executive Vice President of Research and Development since joining Neuraptive in 2019, and will continue to report to Robert Radie, Chairman and CEO. Mr. Tzanis has led the company from a pre-clinical focused company to a clinical staged company with two active INDs cleared and two Phase 2 clinical studies ongoing with Fast Track designation. Additionally, Mr. Tzanis has played an integral role guiding the company through significant organizational transition and fundraising.
In addition, the company has hired Seth Schulman, M.D. as Chief Medical Officer reporting to Mr. Tzanis. Dr. Schulman had previously been consulting with the company. Dr. Schulman is a seasoned drug developer who held roles of increasing responsibility in clinical research from 2004 to 2019 at Wyeth and Pfizer pharmaceuticals, and in 2014, Dr. Schulman became Head of Clinical Sciences Excellence and Innovation in the Global Innovative Pharma Business Unit. Prior to joining Wyeth Pharmaceuticals, Dr. Schulman was a pediatric nephrologist at the Children’s Hospital of Philadelphia (CHOP) and an Associate Professor of Pediatrics and Surgery on the faculty of the University of Pennsylvania School of Medicine. Dr. Schulman has directly overseen hundreds of clinical trials and several product approvals across multiple therapeutic areas including neurology.
“The appointment of Mr. Tzanis to Chief Operating Officer recognizes his successful track record of building high-performing teams and delivering strong results,” said Robert Radie, Neuraptive’s Chairman and CEO. “His expanded role includes oversight and management of manufacturing, quality assurance, regulatory and other key internal company operations.”
“Dr. Schulman is a physician-scientist and clinical and operations leader with extensive experience overseeing and directing end-to-end clinical research and development studies, and I am pleased to have him as part of the Neuraptive team. The appointment of Mr. Tzanis and hiring of Dr. Schulman are aligned to the company’s continued progress toward the eventual NDA filing for its lead program, NTX1-001.”
Finally, the company provided a financial update with the conversion of all previous debt into equity. Over $7.5M in notes converted into preferred shares as the company met certain triggering criteria. The company currently has no outstanding debt.
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005766/en/